Interruption to antiplatelet therapy early after acute ischaemic stroke: a nested case-control study

Mazlan-Kepli, Wardati and Macisaac, Rachael L. and Walters, Matthew and Bath, Philip Michael William and Dawson, Jesse (2017) Interruption to antiplatelet therapy early after acute ischaemic stroke: a nested case-control study. British Journal of Clinical Pharmacology, 83 (9). pp. 2045-2055. ISSN 0306-5251

[img] PDF - Repository staff only until 20 April 2018. - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (71kB)

Abstract

Aims: Antiplatelet drugs are often discontinued early after ischaemic stroke, either because of poor compliance, complications or withdrawal of care. It is unclear whether this places patients at increased risk of recurrence. We explored the association between cardiovascular event rate and persistence with prescribed antiplatelet drugs.

Methods: We used a matched case–control design using the Virtual International Stroke Trials Archive (VISTA). Cases were patients who had an acute coronary syndrome, recurrent stroke or transient ischaemic attack within 90 days post-stroke and were matched for age ± 10 years and sex with up to four controls. Antiplatelet use was categorized as persistent (used for >3 days and continued up to day 90), early cessation (used antiplatelet <3 days) or stopped/interrupted users (used for >3 days but stopped prior to day 90). These categories were compared in cases and controls using a conditional logistic regression model that adjusted for potential confounders.

Results: A total of 970 patients were included, of whom 194 were cases and 776 were matched controls. At 90 days, 10 cases (5.2%) and 58 controls (7.5%) stopped/interrupted their antiplatelet. The risk of cardiovascular event was not different in stopped/interrupted users (adjusted odds ratio 0.70, 95% confidence interval 0.33, 1.48; P = 0.352) and early cessations (adjusted odds ratio 1.04, 95% confidence interval 0.62, 1.74; P = 0.876) when compared to persistent users.

Conclusion: We found no increased risk in patients who stopped and interrupted antiplatelets early after stroke but the study was limited by a small sample size and further research is needed.

Item Type: Article
Schools/Departments: University of Nottingham, UK > Faculty of Medicine and Health Sciences > School of Medicine
Identification Number: 10.1111/bcp.13290
Depositing User: Eprints, Support
Date Deposited: 23 Jan 2018 13:16
Last Modified: 24 Jan 2018 09:28
URI: http://eprints.nottingham.ac.uk/id/eprint/49296

Actions (Archive Staff Only)

Edit View Edit View